210 related articles for article (PubMed ID: 21710357)
21. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
22. [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab].
Sanmartí R; Gómez-Puerta JA; Rodríguez-Cros JR; Albaladejo C; Muñoz-Gómez J; Cañete JD
Med Clin (Barc); 2004 Mar; 122(9):321-4. PubMed ID: 15033049
[TBL] [Abstract][Full Text] [Related]
23. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.
Di Poi E; Perin A; Morassi MP; Del Frate M; Ferraccioli GF; De Vita S
Clin Exp Rheumatol; 2007; 25(1):85-7. PubMed ID: 17417995
[TBL] [Abstract][Full Text] [Related]
24. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study.
Bingham CO; Ince A; Haraoui B; Keystone EC; Chon Y; Baumgartner S
Curr Med Res Opin; 2009 May; 25(5):1131-42. PubMed ID: 19317607
[TBL] [Abstract][Full Text] [Related]
27. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
van Vollenhoven R; Harju A; Brannemark S; Klareskog L
Ann Rheum Dis; 2003 Dec; 62(12):1195-8. PubMed ID: 14644858
[TBL] [Abstract][Full Text] [Related]
28. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
30. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
[TBL] [Abstract][Full Text] [Related]
31. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.
Hirabara S; Takahashi N; Fukaya N; Miyake H; Yabe Y; Kaneko A; Ito T; Oguchi T; Kida D; Hirano Y; Fujibayashi T; Sugiura F; Hayashi M; Funahashi K; Hanabayashi M; Asai S; Ishiguro N; Kojima T
Clin Rheumatol; 2014 Sep; 33(9):1247-54. PubMed ID: 24970596
[TBL] [Abstract][Full Text] [Related]
33. [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
Brocq O; Plubel Y; Breuil V; Grisot C; Flory P; Mousnier A; Euller-Ziegler L
Presse Med; 2002 Nov; 31(39 Pt 1):1836-9. PubMed ID: 12496713
[TBL] [Abstract][Full Text] [Related]
34. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
35. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
36. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
[TBL] [Abstract][Full Text] [Related]
38. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
39. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Hjardem E; Østergaard M; Pødenphant J; Tarp U; Andersen LS; Bing J; Peen E; Lindegaard HM; Ringsdal VS; Rødgaard A; Skøt J; Hansen A; Mogensen HH; Unkerskov J; Hetland ML
Ann Rheum Dis; 2007 Sep; 66(9):1184-9. PubMed ID: 17389656
[TBL] [Abstract][Full Text] [Related]
40. Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Fujii K; Yoshinaga T; Freundlich B; Suzukawa M
Rheumatol Int; 2012 Jun; 32(6):1617-24. PubMed ID: 21331576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
